Kopran Ltd
Kopran Ltd Q2 FY26 Results & Presentation Highlights: Revenue, Margins & Order Book
Q2 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Kopran Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Revenue from Operations for Q2 FY 2025-26: Rs. Quarter (Q2 FY 2025-26) Financials (Page 5): - EBITDA: Rs.
From Kopran Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Revenue from Operations for Q2 FY 2025-26: Rs. 11,791 lakhs
- Revenue from Operations for Q2 FY 2024-25: Rs. 15,156 lakhs
- Year-on-year change: Decline of Rs. 3,365 lakhs (~22.2% decrease)
- Sales/Other Income (HY figures):
- HY FY 2025-26: Rs. 25,331 lakhs
- HY FY 2024-25: Rs. 63,359 lakhs
- Formulations Segment Revenue (Q2 FY 2025-26): Rs. 4,017 lakhs
- Formulations Segment Revenue (HY FY 2025-26): Rs. 9,095 lakhs
- API Segment Revenue (Q2 FY 2025-26): Rs. 8,303 lakhs
2 more points management made on revenue & sales performance
Profitability & Margins
See what Kopran Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Focus on capacity expansion cited under Strategic Imperatives on page 15, no specific amounts or timelines mentioned.
- API and R&D facility at Panoli (Gujarat) mentioned under Strategic Imperatives (page 15) as part of growth strategy, no financials or timelines given.
- Emphasis on development of intermediates for APIs and improving yields/process improvements (page 15), no specific project details or timelines.
- No explicit mention of ongoing or planned capex amounts, new plants, or project completion dates in the presentation.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Kopran Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹234 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Kopran Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Morepen Laboratories Ltd (Q2 FY26)
248 Crores . Key investor presentation takeaways from Morepen Laboratories Ltd's Q2 FY26 investor presentation — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q2 FY26)
Q2’FY26 revenue grew by 12% YoY to Rs. Key investor presentation takeaways from Jubilant Pharmova Ltd's Q2 FY26 investor presentation — and how it ranks against
- Anuh Pharma Ltd (Q2 FY26)
185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. Key investor presentation takeaways from Anuh Pharma Ltd's Q2 FY26 investor presen
- Themis Medicare Ltd (Q2 FY26)
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) . Key investor presentation takeaways from Themis Medicare Ltd's Q2 FY26 inve
Frequently Asked Questions
What were Kopran Ltd Q2 FY26 results?
Revenue from Operations for Q2 FY 2025-26: Rs. Quarter (Q2 FY 2025-26) Financials (Page 5): - EBITDA: Rs.
What is Kopran Ltd share price analysis?
Kopran Ltd currently shows a neutral. The stock trades at a P/E of 53.7 with a market cap of ₹1,342 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kopran Ltd planning capital expenditure?
Focus on capacity expansion cited under Strategic Imperatives on page 15, no specific amounts or timelines mentioned.
Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.